Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein provided clinical benefit to a small group of patients with severe COVID-19. Researchers observed that the off-label use of the cancer drug acalabrutinib, a BTK inhibitor that is approved to treat several blood cancers, was associated with reduced respiratory distress and a reduction in the overactive immune response in most of the treated patients.
- Study helps explain declines in death rates from COVID-19
- Wildfires can cause dangerous debris flows
- Technology shines the light on ovarian cancer treatments
- Thymoquinone induces apoptosis & DNA damage in 5-Fluorouracil-resistant colorectal cancer
- Oncotarget: quantitative ultrasound radiomics in prediction of treatment response for breast cancer